MergerLinks Daily Review

Welcome to MergerLinks Daily Review.?Sign up here?to get the full round up of your daily dose of blue-chip M&A news directly to your inbox.

Chubb completed the acquisition of the personal accident, supplemental health and life insurance business of Cigna for $5.75bn.

NFE and Apollo to form a $2bn joint venture. (Financial Sponsors)?

Zurn Water Solutions completed the merger with Elkay Manufacturing in a $1.56bn deal.

AstraZeneca to acquire TeneoTwo for $1.3bn.

Canadian asset giant Brookfield pours record $12bn into European deals. (FS)

You can access today’s complete newsletter?here.

Scroll down for more…

Chubb completed the acquisition of the personal accident, supplemental health and life insurance business of Cigna for $5.75bn.

Chubb, a global provider of insurance products, completed the acquisition of the personal accident, supplemental health and life insurance business of Cigna, an American multinational managed healthcare and insurance company, for $5.75bn.

"The addition of Cigna's business, which is overwhelmingly A&H, will further balance our global portfolio toward this important region. We have long admired and respected Cigna's business in Asia including its talented people, innovative products, technical and analytical capabilities, distribution and management. Chubb will be better able to capitalize on market and product opportunities with strong brand, complementary direct marketing skills and the cross-selling of Chubb's non-life product to life customers," Evan G. Greenberg, Chubb Chairman and CEO.

Cigna was advised by Ernst & Young and Wachtell Lipton Rosen & Katz. Chubb was advised by Chapman Tripp, Sullivan & Cromwell and Joele Frank.

NFE and Apollo to form a $2bn joint venture. (FS)

NFE, an integrated gas-to-power company, and Apollo, an asset management company, agreed to form a $2bn joint venture, create a global marine infrastructure platform underpinned by long-term contracts.

“Together with Apollo, we are creating a leading LNG marine infrastructure platform to help accelerate the energy transition while freeing up capital to continue to invest into our Fast LNG and downstream LNG projects worldwide. We are pleased to be partnering with Apollo in creating a maritime infrastructure company that will help support NFE’s growing LNG infrastructure needs going forward,” Wes Edens, New Fortress Energy Chairman and CEO.

Zurn Water Solutions completed the merger with Elkay Manufacturing in a $1.56bn deal.

Zurn Water Solutions, a company that provides water solutions and products, completed the merger with Elkay Manufacturing, a commercial drinking water solutions provider, in a $1.56bn deal.

"This transaction is a true game-changer as we create an even stronger pure play water company by combining with the iconic brand, Elkay. The combination puts us well on our way to doubling the size of the business over the next couple of years while enhancing our competitive advantage within specified water solutions. We also add the high-growth, and increasingly essential, drinking water sector in our portfolio and have a clear path to capitalize on the significant synergies the combination will generate," Todd A. Adams, Zurn Water Solutions Chairman and CEO.

Elkay Manufacturing was advised by Citigroup, JP Morgan and Mayer Brown. Financial advisors were advised by Cleary Gottlieb Steen & Hamilton. Zurn Water Solutions was advised by Evercore and Morgan Lewis & Bockius.

AstraZeneca to acquire TeneoTwo for $1.3bn.

AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company, agreed to acquire TeneoTwo, a biotechnology firm, for $1.3bn.

"By redirecting the body's natural immune response to target B-cell malignancies, TNB-486 alone or in combination with CD20-targeted therapy could potentially deepen clinical responses and improve patient outcomes. We believe this innovative molecule, which was designed to optimise the therapeutic window of T-cell activation, will enable us to explore novel combinations that have the potential to become new standards of care in this setting," Anas Younes, AstraZeneca Senior Vice President Haematology R&D.

Canadian asset giant Brookfield pours record $12bn into European deals. (FS)

Brookfield Asset Management is heading into Europe’s swelling market storm with its checkbook open, Bloomberg reported.

As many of its rivals refrain from committing capital to the region amid an ever-growing list of risk factors, the $725bn Canadian investment giant is making plans to buy in sectors ranging from clean energy to technology, open new offices and raise fresh money.

Interested to find more??Sign up here?to get full round up of your daily dose of blue-chip M&A news directly to your inbox.

You can access today’s complete newsletter?here.